The US Just Made Relative Risk Harder To Ignore

• The FDA has authorised a modified risk claim for 20 specific ZYN nicotine pouch products in the U.S. 
• The claim says using ZYN instead of cigarettes puts adult smokers at lower risk of six serious smoking-related diseases. 
• The decision is product-specific, not a blanket endorsement of nicotine pouches or a claim that ZYN is risk-free. 
• As the UK enacts the Tobacco and Vapes Act, harm reduction should be part of the conversation for adults who smoke.

The U.S. Food and Drug Administration (FDA), the regulatory body that oversees tobacco and nicotine products in the United States, has done something that should cut through years of noise in the nicotine debate. It has authorised a modified risk claim for 20 ZYN nicotine pouch products. 

The authorised claim is direct. In the US, these products may now be marketed with the statement that using ZYN instead of cigarettes puts adult smokers at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.

Dr Marina Murphy, Senior Director of Scientific Affairs at Haypp, comments on the FDA authorisation:

 “Public debate too often treats all nicotine products as if they carry the same risk. They do not. Cigarettes involve combustion, and combustion is the central reason smoking remains so harmful. 

Smoke-free nicotine products are different, and adults who smoke deserve information that reflects those differences.”

In the UK, smoking has fallen to historic lows, but it has not disappeared. Around 5.3 million adults still smoked cigarettes in 2024. That means millions of people are still exposed to the risks created by combustion. 

For the UK debate, this is why relative-risk communication matters. Dr Murphy comments: 

“Adult smokers do not benefit from being told that all nicotine products are the same. They benefit from clear, evidence-based information that distinguishes cigarettes from smoke-free alternatives while still making clear that nicotine products are not risk-free.” 

This does not make ZYN risk-free. It does not apply to every nicotine pouch or every ZYN product. It is not a smoking cessation approval, even if many adults do use them to quit smoking. 

But it does mark an important moment: a major regulator has said that relative risk can be communicated clearly, scientifically, and responsibly. 

Dr Murphy continues:

“Adults should not be left to navigate nicotine misinformation in the dark. If the science shows meaningful differences between cigarettes and smoke-free products, regulation should make that information clearer, not harder to access.” 

For adult smokers, clearer information about relative risk is not a marketing issue. It is a public-health issue.